Subscribe

Subscribe Today!

To sign up for our newsletter or print publications, please enter your contact information below.

I'd like to receive:

LATE-BREAKING RESEARCH: Practice Management Research
Abstract #LB04

Time to Treatment Initiation and Outcomes for Patients with Nonmetastatic Breast Cancer Before and During the COVID-19 Pandemic at Community Cancer Centers

JHOP - March 2022 Vol 12 Special Feature - HOPA Abstracts, Breast Cancer

Presenter: Fangzheng Yuan, PharmD, BCPS, Clinical Pharmacy Specialist, Baptist Hospitals of Southeast Texas

Co-Authors: Ahmed Abdelhakeem, MD, Baptist Hospitals of Southeast Texas; Samantha Blevins, RN, Baptist Hospitals of Southeast Texas; Chelsey Peters, RN, OSN, Baptist Hospitals of Southeast Texas; Susan Whalen, BSN, CTR, Baptist Hospitals of Southeast Texas; Ernest Hymel, MD, PhD, Baptist Regional Cancer Network

BACKGROUND: Delays in breast cancer treatment have been associated with increased mortality.1 The COVID-19 pandemic has posed prolonged and significant stress on healthcare resources, which may have affected the quality and outcomes of breast cancer care.2

OBJECTIVE: To compare the time to treatment initiation (TTI) and outcomes in patients with nonmetastatic breast cancer before and during the COVID-19 pandemic.

METHOD: This retrospective study included adult patients with newly diagnosed nonmetastatic breast cancer at 2 community cancer centers of the Baptist Regional Cancer Network (BRCN) in Southeast Texas. Patients diagnosed between January 2018 and June 2019 were included in the control group. Patients diagnosed between April 2020 and September 2021 were included in the COVID-19 group. Patients were excluded if they received initial treatment outside of the BRCN network or for palliative intent. The primary outcome was TTI, defined as time from histologic diagnosis to treatment initiation. The primary analysis was done by t-test. The study had 80% power to detect an absolute increase of 10 days in TTI using a 2-sided alpha of 0.05.

RESULTS: The study included 156 patients—87 patients in the control group and 69 in the COVID-19 group. The median follow-up periods were 37 months (IQR, 32-40 months) in the control group and 8 months (IQR, 6-14 months) in the COVID-19 group. No significant difference in TTI was observed between the control (48.3 days) and the COVID-19 (47.7 days) groups (absolute difference, 0.7; 95% confidence interval, 8.6-10.0; P = .88). After adjusting for initial treatment modality, histology, and clinical stage, the TTI remained similar between the control group and the COVID-19 group (P = .92). No association was noted between the TTI and the number of new COVID-19 cases in the county in the COVID-19 group (P = .85). The proportion of patients diagnosed at disease stage II or III was higher in the COVID-19 group (52.2%) compared with the control group (42.3%), although this was not statistically significant (P = .23). Breast-conserving surgery was done in 26.5% (9/34) of the control group and 55% (11/20) of the COVID-19 group among patients who completed neoadjuvant systemic therapy and surgeries (P = .04). Pathologic complete response was achieved in 58.3% (7/12) of the control group and 14% (1/7) of the COVID-19 group among patients with triple-negative or HER2-positive breast cancer who completed neoadjuvant systemic therapy and surgeries. Overall survival rates at 1 year were 89.7% (78/87) in the control group and 100% (25/25) in the COVID-19 group among patients who reached 1 year after diagnosis (P = .09).

DISCUSSION: No significant delay in breast cancer treatment initiation was observed during the COVID-19 pandemic. Although preliminary outcomes were similar before and during the COVID-19 pandemic, further assessment of the long-term impact of COVID-19 on breast cancer outcomes is needed.

  1. Cone EB, Marchese M, Paciotti M, et al. Assessment of time-to-treatment initiation and survival in a cohort of patients with common cancers. JAMA Netw Open. 2020;3:e2030072. doi: 10.1001/jamanetworkopen.2020.30072.
  2. Bartlett DL, Howe JR, Chang G, et al. Management of cancer surgery cases during the COVID-19 pandemic: considerations. Ann Surg Oncol. 2020;27:1717-1720.
Related Items
Clinical Pharmacist–Initiated Tyrosine Kinase Inhibitor Discontinuation in Patients with Chronic Myeloid Leukemia
JHOP - March 2023 Vol 13 Special Feature published on March 23, 2023 in HOPA Abstracts
Evaluation of Chemotherapy-Induced Myelosuppression in Patients with Extensive-Stage Small-Cell Lung Cancer Who Received Trilaciclib: Retrospective Analysis of Florida Community Oncology Practices
JHOP - March 2023 Vol 13 Special Feature published on March 23, 2023 in HOPA Abstracts
Evaluation of the Safety of the New Alcohol-Containing Formulation of Cyclophosphamide
JHOP - March 2023 Vol 13 Special Feature published on March 23, 2023 in HOPA Abstracts
Health System Specialty Pharmacy Integration Impact on Prescription Fill Time
JHOP - March 2023 Vol 13 Special Feature published on March 23, 2023 in HOPA Abstracts
Invasive Fungal Disease in Patients with Hematologic Malignancies Receiving Micafungin Prophylaxis
JHOP - March 2023 Vol 13 Special Feature published on March 23, 2023 in HOPA Abstracts
Knowledge Gaps and Educational Needs for Common Cancer Therapy–Related Cardiovascular Adverse Events and Related Drug Interactions
JHOP - March 2023 Vol 13 Special Feature published on March 23, 2023 in HOPA Abstracts
Multidisciplinary Approach in Maximizing Oncology Clinic Throughput in a Comprehensive Cancer Center
JHOP - March 2023 Vol 13 Special Feature published on March 23, 2023 in HOPA Abstracts
Optimization of Rasburicase Dose for the Management of Tumor Lysis Syndrome in Community Oncology Practices
JHOP - March 2023 Vol 13 Special Feature published on March 23, 2023 in HOPA Abstracts
Pharmacist-Led 14-Day Oncolytic Drug Check-In Protocol
JHOP - March 2023 Vol 13 Special Feature published on March 23, 2023 in HOPA Abstracts
Safety of Rapid Dose Escalation of Venetoclax in Patients with Hematologic Malignancies
JHOP - March 2023 Vol 13 Special Feature published on March 23, 2023 in HOPA Abstracts
© Amplity Health. All rights reserved.